1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. EQT AB (publ)
  6. News
  7. Summary
    EQT   SE0012853455

EQT AB (PUBL)

(EQT)
  Report
Real-time Estimate Cboe Europe  -  10:39 2022-06-28 am EDT
222.60 SEK   -3.39%
07:19aEuropean Commission Approves EQT, HgCapital, TA Associates' Acquisition of IFS
MT
07:12aEQT Wins European Commission's Nod To Purchase BPEA
MT
06/23Correction to EQT Sells Facile.it Article
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EQT to Delay Plans for $22 Billion Galderma IPO, Reuters Reports

05/13/2022 | 06:11am EDT

--EQT is delaying plans to list its Swiss skin care company Galderma amid market volatility and recession fears in Europe, Reuters reports, citing unnamed sources.

--The potential $22 billion initial public offering was expected to take place in Zurich earlier this year but could now happen in the fall or early next year, Reuters said, citing the sources.

--EQT declined to comment when contacted by Dow Jones Newswires. Galderma couldn't' be reached.


Full story: https://reut.rs/3FFLua0


Write to Ed Frankl at edward.frankl@dowjones.com


(END) Dow Jones Newswires

05-13-22 0811ET

All news about EQT AB (PUBL)
07:19aEuropean Commission Approves EQT, HgCapital, TA Associates' Acquisition of IFS
MT
07:12aEQT Wins European Commission's Nod To Purchase BPEA
MT
06/23Correction to EQT Sells Facile.it Article
DJ
06/23EQT Sells Italian Online Price Comparison Platform Facile.it to Silver Lake
DJ
06/22EQT, Oakley Capital Sell Italian Price Comparison Platform to Silver Lake; Facile Becom..
MT
06/22EQT Private Equity to sell Facile.it, Italy's largest online price comparison platform,..
AQ
06/22EQT's Galderma Says Nemolizumab Benefits Rare Skin Disease Patients in Late-stage Trial
MT
06/22Sweden's EQT to Buy UK-based SPT Labtech for $795 MIllion
MT
06/22EQT Private Equity to acquire SPT Labtech, a fast-growing laboratory automation player ..
AQ
06/22EQT's Galderma announces positive trial results on skin drug
RE
More news
Analyst Recommendations on EQT AB (PUBL)
More recommendations
Financials
Sales 2021 1 461 M 1 550 M 1 550 M
Net income 2021 796 M 845 M 845 M
Net cash 2021 628 M 666 M 666 M
P/E ratio 2021 26,8x
Yield 2021 1,75%
Capitalization 21 490 M 22 802 M 22 802 M
EV / Sales 2021 14,3x
EV / Sales 2022 12,3x
Nbr of Employees 1 059
Free-Float 37,6%
Chart EQT AB (PUBL)
Duration : Period :
EQT AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EQT AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 21,59 €
Average target price 38,13 €
Spread / Average Target 76,6%
EPS Revisions
Managers and Directors
Christian Otto Sinding Chief Executive Officer & Managing Partner
Kim Henriksson Chief Financial Officer
Yngve Conni Jonsson Director
Caspar Mats Andreas Callerstr÷m Chief Operating Officer & Deputy CEO
Gordon Robert Halyburton Orr Independent Director
Sector and Competitors
1st jan.Capi. (M$)
EQT AB (PUBL)-53.27%21 191
PARTNERS GROUP HOLDING AG-40.32%24 721
PETERSHILL PARTNERS PLC-17.49%3 207
BRIDGEPOINT GROUP PLC-45.36%2 726
GOLUB CAPITAL BDC, INC.-16.71%2 198
RATOS AB (PUBL)-21.43%1 487